You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指續受制21,700僅升0.1% 醫藥股跑贏大市 「B仔股」個別續漲逾一成
美國最新通脹年率一如預期連續第六個月回落至6.5%創14個月低,有望美聯儲下月加息幅度縮小至25點子,美股三大指數昨晚反覆續升0.3%-0.6%,惟期貨全面吐近0.2%-0.4%。亞太股市今早除受累於圓匯飆升至近七個月高的日經逆吐1.2%結束五連升外,全部造好,但高位遇壓,目前升幅均收窄至不足1%。 港股連續第三天受制21,700,恆指今早高低見21,651/21,474,現報21,547,僅反覆續升33點或0.1%,總成交額646億元。 醫藥股今天跑贏大市,諾輝健康-B(06606.HK)發盈喜料全年收入升逾2.5倍,股價曾飆升近19%至31.5元(暫受制去年1下旬所造52周高位34.45元),現報29.6元,續升12%,成交增至1,031萬股。 其餘生物科技企業(或俗稱「B仔」股)也普遍受捧,尤其是榮昌生物-B(09995.HK)、康諾亞-B(02162.HK)、心通醫療(02160.HK)及科濟藥業-B(02171.HK)高見69元(創十個月高)、68.9元(創近年半高)、3.45元及19.8元,現報66.85元、67.95元、3.41元及19.68元,續升10%-12%。 兆科眼科-B(06622.HK)回升11.5%報4.5元,創逾半年高。 預計IgA腎病創新藥物Nefecon有望下半年於內地獲批上市的雲頂新耀-B(01952.HK)繼昨天急彈17%後,今早高見24.4元創逾半年高,現報23.95元,續漲7.6%。 東曜藥業-B(01875.HK)續升10%報2.53元。開拓藥業-B(09939.HK)、諾誠健華-B(09969.HK)、貝康醫療-B(02170.HK)及鷹瞳科技-B(02251.HK)依次續升4.5%-9%。 騰盛博藥-B(02137.HK)回升近一成報8.82元;康方生物-B(09926.HK)及三葉草生物-B(02197.HK)回升逾3.5%-4.5%。此外,百濟神州(06160.HK)及藍籌藥明生物(02269.HK)續升5.6%及3.2%,報164元及70.45元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account